Diabetes is a risk factor for knee osteoarthritis progression  by Eymard, F. et al.
Osteoarthritis and Cartilage 23 (2015) 851e859Diabetes is a risk factor for knee osteoarthritis progression
F. Eymard y a, C. Parsons z a, M.H. Edwards z, F. Petit-Dop x, J.-Y. Reginster k, O. Bruyere k,
P. Richette ¶, C. Cooper z b, X. Chevalier y * b
y Department of Rheumatology, AP-HP Henri Mondor Hospital, F-94010 Creteil Cedex, France
z MRC Lifecourse Epidemiology Unit, Southampton General Hospital, SO16 6YD Southampton, UK
x Clinical Department, Servier Laboratory, 92150 Suresnes, France
k Department of Public Health and Health Economics, University of Liege, 4020 Liege, Belgium
¶ Department of Rheumatology, AP-HP Lariboisiere Hospital, F-75475 Paris Cedex 10, Francea r t i c l e i n f o
Article history:
Received 13 October 2014
Accepted 23 January 2015
Keywords:
Knee osteoarthritis
Radiological progression
Metabolic syndrome
Diabetes
Obesity* Address correspondence and reprint requests to:
Rheumatology, AP-HP Henri Mondor Hospital, F-9401
E-mail address: xavier.chevalier@hmn.aphp.fr (X.
a The authors Eymard and Parsons contributed equ
b The authors Cooper and Chevalier contributed eq
http://dx.doi.org/10.1016/j.joca.2015.01.013
1063-4584/© 2015 Osteoarthritis Research Society Ins u m m a r y
Purpose: Recent studies have suggested that metabolic factors (obesity, diabetes, hypertension and
dyslipidemia) and their clustering in metabolic syndrome (MetS) might be involved in the pathophys-
iology of knee osteoarthritis (OA). We investigated their impact on radiographic progression by an
annualised measure of the joint space narrowing (JSN) of the medial tibiofemoral compartment.
Methods: 559 patients older than 50 years with symptomatic knee OA were recruited for the placebo
arm of the SEKOIA trial. The presence of diabetes, hypertension and dyslipidemia was determined at
baseline interview. Body mass index (BMI) was calculated, obesity was considered >30 kg/m2. MetS was
deﬁned by the sum of metabolic factors 3. Minimal medial tibiofemoral joint space on plain radio-
graphs was measured by an automated method at baseline and then annually for up to 3 years.
Results: The mean age of patients was 62.8 [62.2e63.4] years; 392 were women. A total of 43.8% was
obese, 6.6% had type 2 diabetes, 45.1% hypertension, 27.6% dyslipidemia and 13.6% MetS. Mean
annualised JSN was greater for patients with type 2 diabetes than without diabetes (0.26 [0.35 to 0.17]
vs 0.14 [0.16 to 0.12] mm; P ¼ 0.001). This association remained signiﬁcant after adjustment for sex,
age, BMI, hypertension and dyslipidemia (P ¼ 0.018). In subgroup analysis, type 2 diabetes was a sig-
niﬁcant predictor of JSN in males but not females. The other metabolic factors and MetS were not
associated with annualised JSN.
Conclusion: Type 2 diabetes was a predictor of joint space reduction in menwith established knee OA. No
relationships were found between MetS or other metabolic factors and radiographic progression.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Knee osteoarthritis (OA) is the most common joint disease1 and
a major source of disability2,3. Risk factors of knee OA are age, fe-
male gender, heritability, misalignment, tears of the central pivot
ligaments and/or menisci, muscle weakness and obesity4e8. The
association of obesity and knee OA was primarily explained by
mechanical overloading on the cartilage. Nonetheless, evidence for
an association of overweight and OA lesions in non-weight-bearing
joints such as digital interphalangeal joints (Risk Ratio ¼ 1.9) hasX. Chevalier, Department of
0 Creteil Cedex, France.
Chevalier).
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ternational. Published by Elsevier Lhighlighted the contribution of a systemic pathway9. Moreover, a
recent study showed that the addition of cardiometabolic clus-
tering to obesity had a cumulative effect on knee OA prevalence in
women10 while several former cross-sectional studies had already
reported an association between OA and hypertension11, dyslipi-
demia12,13, and hyperglycemia13,14.
Clustering of these factors in the so-called metabolic syndrome
(MetS)15e18 is considered an archetype of chronic low-grade
inﬂammation, especially involved in atherosclerosis disease19e21.
This low-grade systemic inﬂammation may also contribute to the
pathophysiology of OA22,23 and several studies attempted to
conﬁrm this hypothesis. Transversal studies evaluating the link
between MetS and knee OA yielded conﬂicting results24e27. How-
ever, two recent longitudinal studies demonstrated a strong cu-
mulative effect of metabolic factors on early-28 or end-stage29 knee
OA incidence. Moreover, type 2 diabetes was recently found antd. All rights reserved.
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(P ¼ 0.023) after adjustment for body mass index (BMI)30.
Yoshimura et al. ﬁrst evaluated the impact of metabolic factors
on radiographic progression of knee osteoarthritic lesions over 3
years28. They showed that obesity and hypertension were inde-
pendent risk factors for radiographic progression and that accu-
mulation of each metabolic factor was also associated with
progression28. Nonetheless, this study did not strictly assess OA
disease progression because authors also included patients without
knee OA (KL grade < 2) at baseline. Moreover, they deﬁned radio-
graphic progression as a worsening of KL grade31, which is weakly
sensitive to small changes32. An accurate approach to radiographic
progression can only be obtained by strict radiographic measure-
ment of joint spacewidth (JSW), and this evaluation is still accepted
as the gold standard in any chondroprotective trials33.
The SEKOIA trial provided a unique opportunity to study the
involvement of metabolic factors in disease progression with an
accurate semi-automatic measurement of JSW in patients with
symptomatic knee OA. Themain purpose of this studywas to assess
the involvement of each metabolic factor (obesity, diabetes, hy-
pertension, dyslipidemia) and of their clustering in MetS on knee
OA progression. Secondary endpoints included the evaluation of an
association of ischemic disease and knee OA progression and the
impact of metabolic factors on pain and function in knee OA.Material and methods
Characteristics of SEKOIA study
SEKOIA was a randomised, double blind, placebo-controlled
phase 3 trial of outpatients with symptomatic knee OA performed
in 98 centres in 18 countries. This 3-year study compared the
effectiveness of strontium ranelate (1 or 2 g/day) and placebo on OA
radiographic progression and symptoms34. We conducted a post-
hoc analysis of the placebo arm.Study design and patients
All details of study design and inclusion criteria were described
previously34,35. Brieﬂy, the study included Caucasian ambulatory
men and women aged 50 years with symptomatic and radio-
graphic evidence of knee OA according to American College of
Rheumatology criteria36 and the KL scale31, respectively. Radio-
graphic inclusion criteria included OA features deﬁned by KL grade
2 [deﬁnite osteophytes and possible joint space narrowing (JSN)] or
grade 3 (moderate multiple osteophytes, deﬁnite JSN, some scle-
rosis, and possible deformity of bone ends) and JSW of the medial
tibiofemoral compartment of 2.5e5 mm. If both knees fulﬁlled the
selection criteria, the target knee was the most painful; if both
knees were equally painful, the target knee had the highest KL
grade and/or the lowest JSW; and if both knees had the same
radiographic score, the target knee was determined by the in-
vestigator's judgement. Exclusion criteria were knee prosthesis,
recent intra-articular injection (notably glucocorticoids <3 months
previously or hyaluronic acid <6 months previously), clinical de-
formities, secondary knee OA, previous treatments for cartilage or
bone metabolism (e.g., oral or intravenous bisphosphonates <1
year previously, teriparatide or raloxifene <7 days before selection,
and oral glucosamine 1500 mg/day and chondroitin sulphate <3
months previously), and a history or a high risk of venous throm-
boembolism (contraindication for strontium ranelate).Baseline examination
The presence or absence of diabetes mellitus, hypertension and
dyslipidemia was determined at baseline interview according to
medical past history reported by patients. In the design of the
study, medical database included only keywords « diabetes melli-
tus », « type 1 diabetes mellitus » and « type 2 diabetes mellitus ».
Thus, the patients with other type of diabetes such as
glucocorticoid-induced diabetes or unknown type of diabetes were
all included in the group “diabetes mellitus” but not in the sub-
groups “type 1 diabetes mellitus” or “type 2 diabetes mellitus”. The
sum of metabolic factors (obesity, diabetes mellitus, hypertension
and dyslipidemia) was calculated. MetS was deﬁned by the sum of
metabolic factors3. A history of ischemic disease such as ischemic
heart disease, cerebral ischemic disease and peripheral arterial
vascular disease was noted. Height and weight were measured and
BMI was calculated; obesity was considered >30 kg/m2.
Other investigations involved the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC) and global
knee pain [visual analog scale (VAS)] at inclusion. WOMAC evalu-
ates OA health status and outcomes with 24 questions37 summa-
rized as a total score and pain, stiffness and physical function
subscores. For each question, we used a 100-mm scale, with a
maximal score of 2400 mm for the total score, 500 mm for pain,
200 mm for stiffness, and 1700 mm for physical function, lower
scores indicating better status.
Radiographic assessment
Posteroanterior knee radiographs were performed on both
knees at inclusion and then annually on the target knee alone by
use of a standardised technique38. A reproductible knee ﬁxed
ﬂexion (20) was achieved using a SynaFlexer positioning frame
(Synarc Inc., San Francisco, CA, USA). The X-ray beamwas tilted at a
ﬁxed angle of 10 to optimise alignment of themedial tibial plateau.
Quality control (Synarc Inc., Hamburg) included speciﬁcations for
image acquisition and collection (e.g., depiction, positioning and
beam angle), regular training for radiology technicians, determi-
nation of radiographic eligibility and onsite and centralised digiti-
sation and quality control of radiographs35.
Minimal JSW (mm) at the medial tibiofemoral compartment
was measured by a standardised computer-assisted method35,39.
Brieﬂy, magniﬁcation was determined (radio-opaque ruler) and a
region of interest was delimited by a horizontal tangent to the
inferior edges of each femoral condyle and two perpendiculars to
the condylar margins. Within an area deﬁned automatically by two
parallel lines 15 mm apart (with one 10 mm from the condyle line),
the observer delineated the tibial and femoral bone margins to
depict a polygon; JSW was the diameter of the smallest circle
(automatically calculated) in this polygon.
All radiographs were measured centrally (INSERM UMR 1033,
Lyon, France) by a single reader blinded to treatment allocation and
patient identity. Each blinded post-baseline imagewasmeasured in
comparison with the inclusion image to optimise reproducibility
and sensitivity40e42. Intrareader reproducibility was evaluated
yearly with 70 knee radiographs unlinked to the study; reproduc-
ibility was satisfactory (intraclass correlation coefﬁcient for JSW
>0.90)40. Annualised JSN was calculated as the ratio of total JSN
over the study duration to number of years until exit from or the
end of the study.
Statistical analysis
Baseline characteristics are presented as number (%) or
mean ± SD. Annualised JSN values and WOMAC scores are
F. Eymard et al. / Osteoarthritis and Cartilage 23 (2015) 851e859 853presented as mean (SD) and median (quartile 1, quartile 3),
respectively. A t test was used to assess the association of each
metabolic or clinical factor and annualised JSN. The association of
the sum of metabolic factors was assessed by one-way ANOVA. We
used a multivariate linear regression analysis to adjust for age, sex,
BMI and each metabolic factor. The effect of metabolic factors on
WOMAC scores was studied by a ManneWhitney test. P < 0.05 was
considered statistically signiﬁcant.Results
Demographic characteristics of the placebo group
In total, 559 patients were randomly allocated to the placebo
group of the SEKOIA trial; 87 were excluded from the intent-to-
treat (ITT) analysis because of lack of data on baseline evaluation
(n ¼ 1), post-baseline evaluation (n ¼ 87) or treatment (n ¼ 3).
Among all placebo patients, 392 (70%) were women and the mean
age was 62.8 [62.2e63.4] years. The mean BMI was 29.8
[29.4e30.2] kg/m2 and 245 patients (43.8%) were obese. 51 patients
(9.1%) had diabetes mellitus, which was speciﬁed as a type 2 dia-
betes mellitus in 37 patients (6.6%) and a type 1 diabetes mellitus in
one patient (0.2%). 252 (45.1%) had hypertension, 154 (27.6%) had
dyslipidemia, and 76 (13.6%) had MetS (Table I). Moreover, 75 pa-
tients (13.4%) had a history of ischemic disease.Table I
Demographic data for patients with knee OA in the placebo group of the SEKOIA trial
All patients (n ¼ 559)
Age (years) 62.8 [62.2e63.4]
Weight (kg) 80.8 [79.5e82.1]
Height (cm) 164.6 [163.8e165.4]
BMI (kg/m2) 29.8 [29.4e30.2]
Obesity (BMI > 30 kg/m2) 245 (43.8%)
Smoking
No 359 (64%)
Past user 142 (25%)
Current user 58 (10%)
Alcohol consumption
No 284 (51%)
Past user 8 (1%)
Current user 267 (48%)
Disease duration (months) 74.8 [68.5e81.1]
KellgreneLawrence grade
Grade 2 350 (63%)
Grade 3 209 (37%)
Knee JSW at baseline (mm) 3.51 [3.44e3.58]
Knee pain VAS (0e100 mm) 53.7 [51.8e55.6]
WOMAC score*
Total (/2400 mm) 998.5 [955.7e1041.3]
Pain (/500 mm) 211.2 [202.2e220.2]
Stiffness (/200 mm) 91.1 [86.9e95.3]
Physical function (/1700 mm) 694.7 [663.0e726.4]
Physical assessment at baseline
Swelling 104 (18.7%)
Warmth 22 (3.9%)
Effusion 72 (12.9%)
Diabetes mellitusy 51 (9.1%)
Type 1 1 (0.2%)
Type 2 37 (6.6%)
Hypertension 252 (45.1%)
Dyslipidemia 154 (27.6%)
Metabolic syndromez 76 (13.6%)
Ischemic diseases 75 (13.4%)
Ischemic heart disease 60 (10.8%)
Ischemic cerebral disease 11 (2.0%)
Peripheral arterial disease 4 (0.7%)
Data are number of patients (%) or mean [95%CI].
* Each WOMAC item is measured on a 100-mm scale.
y “Diabetes mellitus” subset includes all patients reporting diabetes mellitus at baselin
z Metabolic syndrome is deﬁned by the sum of metabolic factors 3.On 559 target knees, 551 were selected because more painful or
with higher KL grade and/or lower JSW while only 8 (1.43%) were
determined by the investigator's judgement. At baseline, mean
knee pain assessed by VAS was 53.7 [51.8e55.6] mm and mean
WOMAC scores were 998.5 [955.7e1041.3], 211.2 [202.2e220.2],
91.1 [86.9e95.3] and 694.7 [663.0e726.4] for total score and pain,
stiffness and physical function, respectively. Radiological staging
showed that 350 patients (63%) had a KL grade 2 and 209 (37%) a KL
grade 3. Mean JSW at the medial femorotibial compartment was
3.51 [3.44e3.58] mm at baseline (Table I). There was no signiﬁcant
difference in the JSWat baseline depending on the presence of each
metabolic factor or their accumulation.Role of diabetes in knee OA progression in the ITT sample of the
placebo arm
The mean annualised JSN was greater in patients with type 2
diabetes than those without diabetes (0.26 [0.35 to 0.17]
vs 0.14 [0.16 to 0.12] mm; P ¼ 0.001) (Table II). Multivariate
analysis adjusting for age, sex, BMI, hypertension and
dyslipidemia conﬁrmed the independent role of type 2 diabetes
(b ¼ 0.12 [0.22 to 0.02], P-value ¼ 0.018) (data not shown). In
subgroup analysis, the association between type 2 diabetes and
annualised JSNwas found inmales (0.38 [0.57 to0.19] vs0.16Males (n ¼ 167) Females (n ¼ 392)
63.8 [62.6e65.0] 62.3 [61.6e63.0]
90.8 [88.7e92.9] 76.5 [75.0e78.0]
174.7 [173.5e175.9] 160.3 [159.6e161.0]
29.8 [29.2e30.4] 29.8 [29.3e30.3]
67 (40.1%) 178 (45.4%)
79 (47%) 280 (71%)
67 (40%) 75 (19%)
21 (13%) 37 (9%)
39 (23%) 245 (63%)
4 (2%) 4 (1%)
124 (74%) 143 (36%)
88.7 [75.1e102.3] 68.9 [62.1e75.7]
103 (62%) 247 (63%)
64 (38%) 145 (37%)
3.65 [3.53e3.77] 3.45 [3.37e3.53]
48.4 [44.9e51.9] 56.1 [53.8e58.4]
899.2 [820.1e970.3] 1040.4 [990.1e1090.7]
194.9 [178.8e211.0] 218.1 [207.3e228.9]
83.2 [75.9e90.5] 94.4 [89.3e99.5]
618.3 [559.9e676.7] 727.4 [690.1e764.7]
30 (18.1%) 74 (18.9%)
8 (4.8%) 14 (3.6%)
27 (16.3%) 45 (11.5%)
17 (10.2%) 34 (8.7%)
1 (0.6%) 0 (0.0%)
14 (8.4%) 23 (5.9%)
73 (43.7%) 179 (45.7%)
51 (30.5%) 103 (26.3%)
23 (13.8%) 53 (13.5%)
36 (21.6%) 39 (10.0%)
30 (18.0%) 30 (7.7%)
4 (2.4%) 7 (1.8%)
2 (1.2%) 2 (0.5%)
e;
Table II
Univariate analyse of knee OA progression by metabolic factors and ischemic diseases in the intent-to-treat population of the placebo arm of the SEKOIA trial
Annualised JSN (mm)
All patients (n ¼ 472) Males (n ¼ 146) Females (n ¼ 326)
Obesity (BMI  30 kg/m2)
No 0.15 [0.18 to 0.12] (n ¼ 269) 0.18 [0.25 to 0.11] (n ¼ 89) 0.13 [0.16 to 0.10] (n ¼ 180)
Yes 0.15 [0.19  to 0.11] (n ¼ 203) 0.16 [0.23 to 0.09] (n ¼ 57) 0.14 [0.18 to 0.10] (n ¼ 146)
P-value 0.988 0.672 0.615
Diabetes mellitus*
No 0.14 [0.16 to 0.12] (n ¼ 430) 0.16 [0.21 to 0.11] (n ¼ 132) 0.13 [0.16 to 0.10] (n ¼ 298)
Yes 0.21 [0.29 to 0.13] (n ¼ 42) 0.35 [0.52 to 0.18] (n ¼ 14) 0.14 [0.20 to 0.08] (n ¼ 28)
P-value 0.093 0.027 0.831
Diabetes type 2
No 0.14 [0.16 to 0.12] (n ¼ 443) 0.16 [0.21 to 0.11] (n ¼ 134) 0.13 [0.16 to 0.10] (n ¼ 309)
Yes 0.26 [0.35 to 0.17] (n ¼ 29) 0.38 [0.57 to 0.19] (n ¼ 12) 0.19 [0.28 to 0.10] (n ¼ 17)
P-value 0.001 0.016 0.333
Hypertension
No 0.14 [0.17 to 0.11] (n ¼ 260) 0.17 [0.23 to 0.11] (n ¼ 85) 0.12 [0.15 to 0.09] (n ¼ 175)
Yes 0.15 [0.19 to 0.11] (n ¼ 212) 0.19 [0.28 to 0.10] (n ¼ 61) 0.14 [0.18 to 0.10] (n ¼ 151)
P-value 0.494 0.663 0.533
Dyslipidemia
No 0.14 [0.17 to 0.11] (n ¼ 342) 0.19 [0.25 to 0.13] (n ¼ 103) 0.13 [0.16 to 0.10] (n ¼ 239)
Yes 0.15 [0.19 to 0.11] (n ¼ 130) 0.15 [0.22 to 0.08] (n ¼ 43) 0.15 [0.20 to 0.10] (n ¼ 87)
P-value 0.765 0.544 0.379
Sum of metabolic factors
0 0.13 [0.17 to 0.09] (n ¼ 147) 0.16 [0.24 to 0.08] (n ¼ 48) 0.12 [0.17 to 0.07] (n ¼ 99)
1 0.14 [0.18 to 0.10] (n ¼ 142) 0.19 [0.29 to 0.09] (n ¼ 45) 0.12 [0.16 to 0.08] (n ¼ 97)
2 0.15 [0.20 to 0.10] (n ¼ 118) 0.17 [0.27 to 0.07] (n ¼ 33) 0.15 [0.21 to 0.09] (n ¼ 85)
3 0.17 [0.24 to 0.10] (n ¼ 51) 0.20 [0.36 to 0.04] (n ¼ 16) 0.16 [0.23 to 0.09] (n ¼ 35)
4 0.15 [0.25 to 0.05] (n ¼ 14) 0.17 [0.39 to 0.05] (n ¼ 4) 0.14 [0.26 to 0.02] (n ¼ 10)
P-value 0.918 0.980 0.882
Metabolic Syndromey
No 0.14 [0.17 to 0.11] (n ¼ 407) 0.17 [0.22 to 0.12] (n ¼ 126) 0.13 [0.16 to 0.10] (n ¼ 281)
Yes 0.17 [0.23 to 0.11] (n ¼ 65) 0.20 [0.33 to 0.07] (n ¼ 20) 0.15 [0.21 to 0.09] (n ¼ 45)
P-Value 0.503 0.731 0.555
Ischemic diseases
Ischemic heart disease
No 0.14 [0.16 to 0.12] (n ¼ 421) 0.19 [0.24 to 0.14] (n ¼ 123) 0.12 [0.15 to 0.09] (n ¼ 298)
Yes 0.17 [0.25 to 0.09] (n ¼ 51) 0.12 [0.23 to 0.01] (n ¼ 23) 0.21 [0.32 to 0.10] (n ¼ 28)
P-value 0.433 0.379 0.060
Ischemic cerebral disease
No 0.15 [0.17 to 0.13] (n ¼ 462) 0.18 [0.23 to 0.13] (n ¼ 142) 0.13 [0.16 to 0.10] (n ¼ 320)
Yes 0.10 [0.21 to 0.01] (n ¼ 10) 0.04 [0.21 to 0.13] (n ¼ 4) 0.13 [0.28 to 0.02] (n ¼ 6)
P-value 0.540 0.362 0.983
Peripheral arterial disease
No 0.15 [0.17 to 0.13] (n ¼ 469) 0.18 [0.23 to 0.13] (n ¼ 145) 0.13 [0.16 to 0.10] (n ¼ 324)
Yes 0.01 [0.16 to 0.18] (n ¼ 3) 0.2 (n ¼ 1) 0.08 [0.09 to 0.07] (n ¼ 2)
P-value 0.293 e 0.729
Data are mean [95% CI] (n) change in joint space per year.
* “Diabetes mellitus” subset includes all patients reporting diabetes mellitus at baseline.
y Metabolic syndrome is deﬁned by the sum of metabolic factors 3.
F. Eymard et al. / Osteoarthritis and Cartilage 23 (2015) 851e859854[0.21 to 0.11] mm, P ¼ 0.016) but not females (0.19 [0.28
to 0.10] vs 0.13 [0.16 to 0.10] mm, P ¼ 0.333) (Table II).
Obesity, hypertension and dyslipidemia had no impact on
annualised JSN (0.15 [0.19 to 0.11] vs 0.15 [0.18 to 0.12]
mm, P ¼ 0.988; 0.15 [0.19 to 0.11] vs 0.14 [0.17 to 0.11]
mm, P ¼ 0.494 and 0.15 [0.19 to 0.11] vs 0.14 [0.17
to 0.11] mm, P ¼ 0.765, respectively) (Table II). Similar results
were found for males and females. Moreover, we found neither
cumulative effect of metabolic factors on knee OA progression (all
patients: P ¼ 0.918, males: P ¼ 0.980 and females: P ¼ 0.882) nor
association between MetS and annualised JSN (all patients: 0.17
[0.23 to 0.11] vs 0.14 [0.17 to 0.11] mm, P ¼ 0.503,
males: 0.20 [0.33 to 0.07] vs 0.17 [0.22 to 0.12] mm,
P ¼ 0.731 and females: 0.15 [0.21 to 0.09] vs 0.13 [0.16
to 0.10] mm, P ¼ 0.555) (Table II). Arteriosclerotic vascular dis-
eases including ischemic heart disease, ischemic cerebral disease
and peripheral arterial disease did not seem to be involved in knee
OA progression, although we found a trend towards a positive
association between ischemic heart disease and annualised JSN infemales (0.21 [0.32 to 0.10] vs 0.12 [0.15 to 0.09] mm,
P ¼ 0.060) (Table II).
Impact of metabolic factors on pain and function at baseline
Among metabolic factors, obesity was the sole factor associated
with worsening pain, stiffness and physical function score (241 vs
177, P < 0.0001; 106 vs 81, P ¼ 0.0003 and 809 vs 557, P < 0.0001),
respectively) (Table III). Almost all WOMAC subscores were higher
but not signiﬁcantly in the presence of one of the metabolic factors,
except for the stiffness subscore in patients with hypertension and
type 2 diabetes (Table III). Similarly, MetS was not signiﬁcantly
associated with worsening WOMAC subscores (288 vs 199,
P ¼ 0.243 for pain score; 101.5 vs 94, P ¼ 0.691 for stiffness score
and 758.9 vs 645.5, P ¼ 0.241 for function score) (Table III). We
found no association between WOMAC subscores and ischemic
diseases, except for ischemic cerebral disease signiﬁcantly associ-
ated with stiffness and physical function subscores (124 vs 94,
P ¼ 0.032 and 881 vs 658, P ¼ 0.040, respectively) (Table III).
Table III
Involvement of metabolic factors in symptoms of knee OA by WOMAC subscores at baseline
WOMAC Pain score (/500 mm) (n ¼ 551) WOMAC stiffness (/200 mm) (n ¼ 557) WOMAC physical function score
(/1700 mm) (n ¼ 554)
Obesity (BMI  30 kg/m2)
No 177 (113; 262) (n ¼ 308) 81 (44; 123) (n ¼ 312) 557 (310; 864) (n ¼ 311)
Yes 241 (159; 326) (n ¼ 243) 106 (60; 137) (n ¼ 245) 809 (540; 1137) (n ¼ 243)
P-value <0.0001 0.0003 <0.0001
Diabetes mellitus*
No 200 (122; 288) (n ¼ 500) 95 (49; 132) (n ¼ 506) 653 (387; 973) (n ¼ 503)
Yes 226 (147; 291) (n ¼ 51) 101 (54; 121) (n ¼ 51) 751 (391; 1028) (n ¼ 51)
P-value 0.407 0.872 0.615
Diabetes type 2
No 201 (122; 287) (n ¼ 514) 97 (50; 131) (n ¼ 520) 658 (393; 976) (n ¼ 517)
Yes 220 (164; 286) (n ¼ 37) 93 (54; 123) (n ¼ 37) 712 (387; 886) (n ¼ 37)
P-value 0.656 0.995 0.909
Hypertension
No 200 (116; 277) (n ¼ 303) 98 (48; 133) (n ¼ 305) 613 (361; 949) (n ¼ 303)
Yes 209 (136; 291) (n ¼ 248) 95 (53; 123) (n ¼ 252) 731 (418; 1002) (n ¼ 251)
P-value 0.195 0.927 0.082
Dyslipidemia
No 192 (121; 281) (n ¼ 400) 91 (47; 132) (n ¼ 403) 638 (378; 949) (n ¼ 401)
Yes 226 (138; 294) (n ¼ 151) 102 (61; 124) (n ¼ 154) 725 (410; 1020) (n ¼ 153)
P-value 0.059 0.382 0.128
Metabolic Syndromey
No 199 (122; 287) (n ¼ 475) 94 (49; 132) (n ¼ 481) 645.5 (381; 952) (n ¼ 478)
Yes 288 (153; 291) (n ¼ 76) 101.5 (58; 120.5) (n ¼ 76) 758.9 (414; 1017) (n ¼ 76)
P-value 0.243 0.691 0.241
Ischemic diseases
Ischemic heart disease
No 200 (122; 288) (n ¼ 493) 96 (50; 132) (n ¼ 498) 649 (383; 949) (n ¼ 494)
Yes 231 (138; 274) (n ¼ 58) 99 (51; 123) (n ¼ 59) 796 (485; 1023) (n ¼ 60)
P-value 0.344 0.957 0.084
Ischemic cerebral disease
No 201 (122; 288) (n ¼ 540) 94 (49; 130) (n ¼ 546) 658 (384; 973) (n ¼ 543)
Yes 237 (184; 299) (n ¼ 11) 124 (95; 154) (n ¼ 11) 881 (770; 1070) (n ¼ 11)
P-value 0.203 0.032 0.040
Peripheral arterial disease
No 203 (125; 288) (n ¼ 548) 97 (50; 130) (n ¼ 553) 668 (392; 973) (n ¼ 550)
Yes 58 (49; 239) (n ¼ 3) 45 (9; 109) (n ¼ 4) 574 (104; 1045) (n ¼ 4)
P-value 0.123 0.227 0.549
Data are median (quartile 1; quartile 3).
* “Diabetes mellitus” subset includes all patients reporting diabetes mellitus at baseline.
y Metabolic syndrome is deﬁned by the sum of metabolic factors 3.
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Our study is the ﬁrst to evaluate the link between metabolic
factors and radiographic progression of knee OA based on an annual
accurate measure of JSN. We showed that type 2 diabetes was
associated with a greater radiographic progression in males. The
only other study evaluating radiographic knee OA progression also
highlighted the potential effect of diabetes on disease progres-
sion28: knee OA patients with hemoglobin A1c 5.5% had a greater
risk of disease progression over 3 years (P¼ 0.029) after adjustment
for age and sex. However, this association disappeared after
adjustment for other OA risk factors and others components of the
MetS.
How diabetes might interfere with the OA disease process?
Hyperglycemia may lead to glycation of cartilage resident proteins
especially those exhibiting low turnover such as type II collagen43.
By changing their physical properties, this glycation could increase
the stiffness of cartilage collagen network and so reduce its resis-
tance to mechanical stress44. Moreover, several recent studies
highlighted a central role of advanced glycation end products (AGE)
and their receptors (RAGE) in the inﬂammatory and degradative
process in OA. AGE enhanced the production of interleukin 6 and
matrix metalloproteinase (MMP)-13 and the expression of cyclo-
oxygenase 2 and reduced that of collagen II in human OA chon-
drocytes45. Steenvoorden et al. showed a catabolic effect on humanOA synoviocytes induced by glycated albumin, with an increase in
MMP-1 production and catabolic activity46. Otherwise, the associ-
ation between diabetes and knee OA could also involve the pro-
duction of reactive oxygen species (ROS) by OA chondrocytes,
which is increased in response to prolonged hyperglycemia and
known to induce degradation of cartilage matrix proteins47.
The speciﬁc link between knee OA and diabetes in males had
already been suggested in a previous study27. Indeed, in obese
subjects, knee OA prevalence was associated with insulin resistance
only in males [OR ¼ 1.34 (1.27e1.42) in males and OR ¼ 0.88
(0.86e0.89) in females]. However, we have no clear explanation of
this speciﬁc association, although both basic and clinical studies
may provide some explanation. Selvin et al. recently showed that
male sex was associated with a lower level of soluble RAGE
(sRAGE), which are suspected to partially counteract the pro-in-
ﬂammatory effect of AGE by decreasing their binding on RAGE48.
However, this hypothesis remains controversial, given the very low
level of sRAGE as compared with circulating AGE49,50. Another
explanation could be provided by the gender speciﬁties of diabetic
complications51e56. Indeed, distal neuropathy seems to occur more
frequently and earlier in diabetic men as compared with diabetic
women52,55,56. Furthermore, a recent study showed diabetic poly-
neuropathy was associated with increased rate of bone turnover in
males assessed by different biomarkers (e.g., C-terminal telopep-
tide 1, propeptide of human procollagen type I, osteocalcin)53.
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be due in part to indirect consequences of neuropathy both on pain
sensitivity compromising the joint saving57 and on metabolism of
tissues such as bone implicated in the OA pathophysiology53. Un-
fortunately, we lack this kind of information in the baseline de-
mographic data in SEKOIA trial.
Obesity was not associated with disease progression over the
study duration. This result seems all themore surprising since there
was a strong association between weight status and the severity of
clinical symptoms at baseline, which had already been identiﬁed as
linked with radiological progression58,59. Thus, we may expect that
obese patient who were the most painful, had a proﬁle of a more
rapid radiological progression. However, pain intensity could be
considered as a confounding factor, more reﬂecting the extension of
joint damage (such as bone edema or rapid chondrolysis) rather
than directly inﬂuencing knee OA progression. Moreover, clinical
symptoms were collected at baseline and did not necessarily reﬂect
the level of pain throughout the study. Moreover, as only 17.2% of
patients had a normal weight (<25 kg/m2), it was methodologically
difﬁcult to realize any valid comparison between obese
(BMI  30 kg/m2) or overweight patients (25 kg/m2 < BMI < 30 kg/
m2) and normal patients (BMI < 25 kg/m2) and so we only
compared obese patients to others, having either normal BMI or
more frequently overweight, which could hide the effect of obesity
on radiological progression. Actually, although obesity is consid-
ered a key factor of knee OA progression, a detailed review of the
literature provided conﬂicting data: long-term follow-up studies
indicated that obesity is a strong risk factor for knee OA pro-
gression60e62, but other studies with a shorter follow-up provided
opposite results, showing no robust association5,63,64. Similarly, in
our study, the short follow-up could be insufﬁcient to observe an
effect of overweight, especially because most patients had a BMI
>25 kg/m2. Otherwise, these conﬂicting results may be linked to
differences in the “phenotype” of knee OA. Several studies high-
lighted a crucial effect of the association of misalignment plus
obesity on knee OA progression63,65,66. In the SEKOIA trial,
excluding patients with signiﬁcant misalignment could explain the
lack of effect of obesity on knee OA progression.
Like obesity, dyslipidemia and hypertension did not seem to
affect radiographic progression of knee OA. However, Yoshimura
et al. showed hypertension, deﬁned as systolic blood pressure
>130 mm Hg and/or diastolic blood pressure >85 mm Hg or
medication intake, as a risk factor of disease progression (RR¼ 1.54)
even after adjustment for BMI and other metabolic factors28. Unlike
Yoshimura et al., we did not ﬁnd any cumulative effect of metabolic
factors on radiographic progression over 3 years, which is consis-
tent with our results showing a unique role of diabetes.
Concerning the clinical symptoms, obesity was the sole meta-
bolic factor signiﬁcantly associatedwith pain, stiffness and function
assessed by WOMAC scores. Unlike Schett et al.30, we found no
association of diabetes and symptom severity in our study.
Our study presents some limitations. First of all, this was a post-
hoc analysis, not included in the initial design of the SEKOIA trial.
Furthermore, the deﬁnition of metabolic factors in SEKOIA was
based solely on medical history without blood pressure measure-
ment or a blood test tomeasure lipid and glucose. Consequently, we
selected patients with advanced or well-recognized diseases (at
least by the patient himself), but may ignore those with unrecog-
nized or silent metabolic diseases; this could induce an information
bias by misclassiﬁcation. This bias seems to be conﬁrmed by the
prevalence of metabolic factors (except for obesity) and the SM
noted in our study, which are lower than those found in a French
population of the same age67. Consequently, further studies need to
include validated criteria deﬁned by experts for each metabolic
factor17. Finally, several factors, which may be related to diseaseprogression of knee OAwere not recorded at baseline, such as bone
mass68 but also physical activity69.
Our study also has several strengths. First, we used the placebo
arm of a controlled, multicentre study allowing a rigorous data
collection. Overall, this is the ﬁrst study, which evaluates the
involvement of metabolic factors in radiographic progression of
knee OA using a reliable and reproducible measurement of JSW
rather than the KL grade, which is less accurate, less sensitive to
change and a source of great variability in interpretation.
To conclude, amongmetabolic factors, only diabetes appeared to
be a strong factor associated with radiographic progression of knee
OA in males. These results might open a new therapeutic avenue in
terms of prevention of disease progression with a special focus on
glycemic equilibrium. We did not study the impact of glycemic
control on disease progression since glycemia was not measured in
the SEKOIA trial. However, this hypothesis seems plausible as it has
been shown that a tight glycemic control could reduce the rate of
circulating or tissular AGE70,71 in addition to decrease the blood
glucose, which are potentially involved in OA pathophysiology45e47.
Finally, further longitudinal studies including type 1 diabetes
would be of interest in order to assess the speciﬁc impact of chronic
hyperglycemia (e.g., protein glycation) on OA progression as there
will be less confounding « pro-inﬂammatory factors » such as those
found in type 2 diabetes (obesity, dyslipidemia or hypertension).
However, as type 1 diabetes is a much rarer disease than type 2
diabetes, it is more difﬁcult to form large homogeneous cohorts
with a long-term follow-up.
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